Cargando…

Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme

AIM: To evaluate the potential for semaglutide to help people with type 2 diabetes (T2D) achieve glycated haemoglobin (HbA1c) targets while avoiding unwanted outcomes, such as weight gain, hypoglycaemia and gastrointestinal (GI) side effects. MATERIALS AND METHODS: Data from the phase IIIa SUSTAIN 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeVries, J. Hans, Desouza, Cyrus, Bellary, Srikanth, Unger, Jeffrey, Hansen, Oluf K. H., Zacho, Jeppe, Woo, Vincent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175309/ https://www.ncbi.nlm.nih.gov/pubmed/29862621 http://dx.doi.org/10.1111/dom.13396

Ejemplares similares

Prevalence of Hypoglycaemia among Insulin-Treated Pregnant Women with Diabetes Who Achieved Tight Glycaemic Control
por: Ng, Danish, et al.
Publicado: (2019)

Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme
por: Dungan, K. M., et al.
Publicado: (2016)

The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability
por: Waeschle, Reiner M, et al.
Publicado: (2008)

Impaired awareness of hypoglycaemia in women with type 1 diabetes in pregnancy: Hypoglycaemia fear, glycaemic and pregnancy outcomes
por: Bahrami, Jasmine, et al.
Publicado: (2022)

Early hypoglycaemia and hyperglycaemia and 'tight' glycaemic control with and without glucose infusions
por: Raobaikady, R, et al.
Publicado: (2004)

Factors influencing glycaemic stability after neonatal hypoglycaemia and relationship to neurodevelopmental outcome
por: Burakevych, Nataliia, et al.
Publicado: (2019)

Hypoglycaemia Remains the Key Obstacle to Optimal Glycaemic Control – Continuous Glucose Monitoring is the Solution
por: Adolfsson, Peter, et al.
Publicado: (2018)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

The SAGE study: Global observational analysis of glycaemic control, hypoglycaemia and diabetes management in T1DM
por: Renard, Eric, et al.
Publicado: (2021)

The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus
por: McEwan, Phil, et al.
Publicado: (2016)

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
por: Zinman, Bernard, et al.
Publicado: (2017)

Effect of intensive glycaemic control on moderate hypoglycaemia and ICU length of stay in severe traumatic brain injury
por: Núñez-Patiño, Rafael A., et al.
Publicado: (2018)

Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
por: Aronson, Ronnie, et al.
Publicado: (2018)

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
por: Mauricio, Dídac, et al.
Publicado: (2017)

Correlations between parameters of glycaemic variability and foetal growth, neonatal hypoglycaemia and hyperbilirubinemia in women with gestational diabetes
por: Blasi, Immacolata, et al.
Publicado: (2023)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

Severe neonatal hypoglycaemia and intrapartum glycaemic control in pregnancies complicated by type 1, type 2 and gestational diabetes
por: Yamamoto, J. M., et al.
Publicado: (2019)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
por: Bergenstal, R M, et al.
Publicado: (2013)

Oxidised Met(147) of human serum albumin is a biomarker of oxidative stress, reflecting glycaemic fluctuations and hypoglycaemia in diabetes
por: Momozono, Akari, et al.
Publicado: (2020)

Glycaemic thresholds for counterregulatory hormone and symptom responses to hypoglycaemia in people with and without type 1 diabetes: a systematic review
por: Verhulst, Clementine E. M., et al.
Publicado: (2022)

Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study
por: Bajaj, M, et al.
Publicado: (2014)

Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status
por: Wiegers, Evita C., et al.
Publicado: (2019)

Hypoglycæmia
Publicado: (1934)

Hypoglycaemia following upper gastrointestinal surgery: case report and review of the literature
por: Bernard, Brandon, et al.
Publicado: (2010)

Refractory hypoglycaemia in a localised gastrointestinal stromal tumour: Case report
por: Dhali, Arkadeep, et al.
Publicado: (2021)

Genetic insights into fetal growth and measures of glycaemic regulation and adiposity in adulthood: a family-based study
por: Hollensted, Mette, et al.
Publicado: (2018)

Changes in attitudes to awareness of hypoglycaemia during a hypoglycaemia awareness restoration programme are associated with avoidance of further severe hypoglycaemia episodes within 24 months: the A2A in HypoCOMPaSS study
por: Sepúlveda, Eduardo, et al.
Publicado: (2022)

Insulin Hypoglycæmia
Publicado: (1948)

The consequences of hypoglycaemia
por: Amiel, Stephanie A.
Publicado: (2021)

Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia
por: Kristensen, Peter L, et al.
Publicado: (2016)

A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care (HARPdoc)
por: Amiel, Stephanie A., et al.
Publicado: (2022)

Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild‐to‐moderate renal impairment
por: Javier Escalada, F., et al.
Publicado: (2018)

How Does Social Behavior Relate to Both Grades and Achievement Scores?
por: DeVries, Jeffrey M., et al.
Publicado: (2018)

Hypoglycaemia in adrenal insufficiency
por: Lee, Shien Chen, et al.
Publicado: (2023)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

Glycaemic variability and risk of adverse cardiovascular events in acute coronary syndrome
por: Zhang, Lei, et al.
Publicado: (2022)

Successful Treatment with Bedtime Basal Insulin Added to Metformin without Weight Gain or Hypoglycaemia over Three Years
por: Mertes, Bernardo, et al.
Publicado: (2020)

Developmental Gains in Visuospatial Memory Predict Gains in Mathematics Achievement
por: Li, Yaoran, et al.
Publicado: (2013)

GlucoTab‐guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes
por: Aberer, Felix, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ok12cpfrc0gor8qjgllo7if4gp